U.S. FDA Approves Two Drugs Of India’s Strides Arcolab
This article was originally published in PharmAsia News
Strides Arcolab of India has been cleared by the U.S. FDA to market two drugs aimed at improving blood circulation. One is its dexamethasone injection, the other is dexamethasone sodium phosphate. The drugs are to be marketed through a joint venture Strides has with Akom, Akom-Strides. The drugs are aimed at fluid retention and swelling in the brain, plus problems with blood circulation caused by trauma. (Click here for more
You may also be interested in...
US regulators refused to accept the file for one of Y-mAbs's neuroblasoma drugs – omburtamab – in October but have given the green light to a second one, naxitamab.
Fueled by a pipeline of more than 15 biosimilar candidates, Sandoz is aiming to treble the size of its $2bn global biosimilars business by 2030, targeting the US, Europe and Japan. Management spoke at length about the firm’s achievements and prospects during a meeting of parent Novartis’ management.
Rather than hitting the acquisition trial, Biogen has taken the licensing route to expand its psychiatric and neurological disorders pipeline.